Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$18.15
-0.8%
$14.84
$7.75
$19.93
$138.63M0.6227,558 shs15,693 shs
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
$3.18
$3.39
$2.55
$6.12
$34.28M1.5461,992 shs22,388 shs
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
$0.01
+4.5%
$0.01
$0.00
$0.01
$18.51M-2.4834,004 shs25,000 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
$2.14
$7.94M0.688.94 million shs300 shs
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
$0.34
+4.1%
$0.31
$0.24
$1.47
$24.46M0.13434,142 shs283,192 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-0.82%+6.26%+19.41%+108.38%+49.38%
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
0.00%+1.27%-1.24%+6.35%-25.87%
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
+4.48%-6.67%+18.64%+27.27%+112.12%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%0.00%0.00%0.00%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
+4.08%+0.29%+15.17%+22.16%-54.24%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
3.5646 of 5 stars
3.33.00.04.71.20.00.0
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
2.5094 of 5 stars
3.52.00.00.03.10.80.6
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/AN/AN/AN/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
4.4704 of 5 stars
3.63.00.04.62.22.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
2.67
Moderate Buy$33.0081.82% Upside
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
3.00
Buy$25.00686.16% Upside
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
0.00
N/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
0.00
N/AN/AN/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
3.20
Buy$3.13808.43% Upside

Current Analyst Ratings Breakdown

Latest OBSV, LTRN, OVID, ASMB, and LTUS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$2.00 ➝ $1.50
4/24/2025
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$32.15M4.31N/AN/A$5.25 per share3.46
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
N/AN/AN/AN/A$1.96 per shareN/A
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
N/AN/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/A$0.41 per shareN/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
$570K42.92N/AN/A$0.96 per share0.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$40.18M-$6.23N/AN/AN/A-124.15%-131.77%-36.81%8/6/2025 (Estimated)
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
-$20.78M-$1.84N/AN/AN/AN/A-83.26%-70.65%8/6/2025 (Estimated)
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
$110KN/A0.00N/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
-$26.43M-$0.35N/AN/AN/A-4,562.23%-34.17%-25.34%8/12/2025 (Estimated)

Latest OBSV, LTRN, OVID, ASMB, and LTUS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
-$0.49-$0.42+$0.07-$0.42N/AN/A
5/13/2025Q1 2025
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
-$0.14-$0.14N/A-$0.14$0.03 million$0.13 million
5/8/2025Q1 2025
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$2.01-$1.17+$0.84-$1.17$7.41 million$9.42 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/AN/AN/AN/AN/A
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
N/AN/AN/AN/AN/A
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
N/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/A
2.05
2.05
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
N/A
4.86
4.86
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
N/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/A
0.61
0.61
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
0.22
4.93
4.93

Institutional Ownership

CompanyInstitutional Ownership
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
19.92%
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
28.62%
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
N/A
ObsEva SA stock logo
OBSV
ObsEva
17.52%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
72.24%

Insider Ownership

CompanyInsider Ownership
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
5.30%
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
7.31%
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
N/A
ObsEva SA stock logo
OBSV
ObsEva
14.40%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
13.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
1007.64 million7.23 millionOptionable
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
2010.78 million10.00 millionOptionable
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
2302.64 billionN/ANot Optionable
ObsEva SA stock logo
OBSV
ObsEva
5077.97 million66.74 millionNot Optionable
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
6071.11 million61.80 millionOptionable

Recent News About These Companies

Ovid Therapeutics Inc Chart - Morningstar
Juneberry Farm in Ovid opens for u-pick season
Ovid man, 81, charged with DWI after near-crash
Ovid Therapeutics (OVID) Receives a Buy from TD Cowen

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Assembly Biosciences stock logo

Assembly Biosciences NASDAQ:ASMB

$18.15 -0.15 (-0.82%)
As of 07/3/2025 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Lantern Pharma stock logo

Lantern Pharma NASDAQ:LTRN

$3.18 0.00 (0.00%)
Closing price 07/3/2025 03:05 PM Eastern
Extended Trading
$3.18 0.00 (0.00%)
As of 07/3/2025 04:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Lotus Pharmaceuticals stock logo

Lotus Pharmaceuticals OTCMKTS:LTUS

$0.0070 +0.00 (+4.48%)
As of 07/3/2025 11:21 AM Eastern

Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.

ObsEva stock logo

ObsEva NASDAQ:OBSV

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Ovid Therapeutics stock logo

Ovid Therapeutics NASDAQ:OVID

$0.34 +0.01 (+4.08%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$0.35 +0.01 (+2.91%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.